Lymphoma & CLL Trials

Japanese approval of axicabtagene ciloleucel for the treatment of R/R large B-cell lymphomas

On January 22, 2021, it was announced that the Japanese Ministry of Health, Labour and Welfare approved the...

Clinical and infusion product characteristics influencing the outcomes and toxicity of CAR T-cell treatment with axicabtagene ciloleucel for LBCL

Chimeric antigen receptor (CAR) T-cell therapy...

NICE recommends KTE-X19 for the treatment of R/R MCL

On January 19, 2021, the National Institute for Health and Care Excellence (NICE) for England issued guidance stating that KTE-X19 could be...

KTE-X19 receives conditional approval in Europe for the treatment of relapsed/refractory MCL

On December 16, 2020, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, KTE-X19, was...

5-year results of the MURANO phase III trial of venetoclax + rituximab vs bendamustine + rituximab in patients with CLL

During the 62nd American Society of Hematology (ASH) Annual Meeting and...

Satellite Symposium | Patient with R/R CLL—European perspective

The virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat:...

NCCN recommendation of zanubrutinib as first-line and second-line therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma

On December 3, 2020, the National Comprehensive Cancer Network...

Zanubrutinib shows significant activity in high-risk treatment-naïve patients with del(17p) CLL/SLL in a global phase III trial

Although rare in treatment-naïve patients with chronic lymphocytic...